Logo image of CYCN

CYCLERION THERAPEUTICS INC (CYCN) Stock Price, Quote, News and Overview

NASDAQ:CYCN - Nasdaq - US23255M2044 - Common Stock - Currency: USD

3.3  -0.15 (-4.35%)

CYCN Quote, Performance and Key Statistics

CYCLERION THERAPEUTICS INC

NASDAQ:CYCN (5/1/2025, 4:04:02 PM)

3.3

-0.15 (-4.35%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High9.47
52 Week Low1.27
Market Cap10.59M
Shares3.21M
Float2.24M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-05 2025-05-05
IPO03-18 2019-03-18


CYCN short term performance overview.The bars show the price performance of CYCN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

CYCN long term performance overview.The bars show the price performance of CYCN in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of CYCN is 3.3 USD. In the past month the price increased by 35.83%. In the past year, price increased by 16.75%.

CYCLERION THERAPEUTICS INC / CYCN Daily stock chart

CYCN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.83 342.01B
AMGN AMGEN INC 14.32 152.57B
GILD GILEAD SCIENCES INC 13.34 128.71B
VRTX VERTEX PHARMACEUTICALS INC 1720.21 128.25B
REGN REGENERON PHARMACEUTICALS 13.32 64.50B
ARGX ARGENX SE - ADR 336.79 39.07B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.19B
ONC BEIGENE LTD-ADR N/A 27.55B
BNTX BIONTECH SE-ADR N/A 24.62B
NTRA NATERA INC N/A 20.46B
SMMT SUMMIT THERAPEUTICS INC N/A 18.19B
BIIB BIOGEN INC 7.34 17.71B

About CYCN

Company Profile

CYCN logo image Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The firm operates through the human therapeutics segment. The firm is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The firm is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.

Company Info

CYCLERION THERAPEUTICS INC

301 Binney Street

Cambridge MASSACHUSETTS 02142 US

CEO: Peter M. Hecht

Employees: 1

Company Website: https://www.cyclerion.com/

Investor Relations: http://ir.cyclerion.com/

Phone: 16176217722

CYCLERION THERAPEUTICS INC / CYCN FAQ

What is the stock price of CYCLERION THERAPEUTICS INC today?

The current stock price of CYCN is 3.3 USD. The price decreased by -4.35% in the last trading session.


What is the ticker symbol for CYCLERION THERAPEUTICS INC stock?

The exchange symbol of CYCLERION THERAPEUTICS INC is CYCN and it is listed on the Nasdaq exchange.


On which exchange is CYCN stock listed?

CYCN stock is listed on the Nasdaq exchange.


What is CYCLERION THERAPEUTICS INC worth?

CYCLERION THERAPEUTICS INC (CYCN) has a market capitalization of 10.59M USD. This makes CYCN a Nano Cap stock.


How many employees does CYCLERION THERAPEUTICS INC have?

CYCLERION THERAPEUTICS INC (CYCN) currently has 1 employees.


What are the support and resistance levels for CYCLERION THERAPEUTICS INC (CYCN) stock?

CYCLERION THERAPEUTICS INC (CYCN) has a support level at 2.73 and a resistance level at 3.71. Check the full technical report for a detailed analysis of CYCN support and resistance levels.


Should I buy CYCLERION THERAPEUTICS INC (CYCN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CYCLERION THERAPEUTICS INC (CYCN) stock pay dividends?

CYCN does not pay a dividend.


When does CYCLERION THERAPEUTICS INC (CYCN) report earnings?

CYCLERION THERAPEUTICS INC (CYCN) will report earnings on 2025-05-05.


What is the Price/Earnings (PE) ratio of CYCLERION THERAPEUTICS INC (CYCN)?

CYCLERION THERAPEUTICS INC (CYCN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).


What is the Short Interest ratio of CYCLERION THERAPEUTICS INC (CYCN) stock?

The outstanding short interest for CYCLERION THERAPEUTICS INC (CYCN) is 2.04% of its float. Check the ownership tab for more information on the CYCN short interest.


CYCN Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to CYCN. When comparing the yearly performance of all stocks, CYCN is one of the better performing stocks in the market, outperforming 72.16% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CYCN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CYCN. While CYCN seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CYCN Financial Highlights

Over the last trailing twelve months CYCN reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 46.04% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.93%
ROE -34.54%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%130.22%
Sales Q2Q%N/A
EPS 1Y (TTM)46.04%
Revenue 1Y (TTM)N/A

CYCN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to CYCN. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners16.08%
Ins Owners23.53%
Short Float %2.04%
Short Ratio1.18
Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A